Review
doi: 10.1007/s11914-004-0018-y.
Postmenopausal osteoporosis
Affiliations
- PMID: 16036090
- DOI: 10.1007/s11914-004-0018-y
Item in Clipboard
Review
Postmenopausal osteoporosis
Curr Osteoporos Rep.
2004 Sep.
Abstract
The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of alternative therapies are available for the postmenopausal woman. Furthermore, recent understanding of the mechanisms of bone loss after estrogen withdrawal, suggest that newer even better targeted therapies might be developed in the future.
Similar articles
-
Clinical inquiries. What is the best approach to prevention and treatment of osteoporosis?J Fam Pract. 2001 Dec;50(12):1024-5. J Fam Pract. 2001. PMID: 11742601 Review. No abstract available.
-
Combination/sequential therapy in osteoporosis.Curr Osteoporos Rep. 2004 Dec;2(4):123-30. doi: 10.1007/s11914-996-0011-8. Curr Osteoporos Rep. 2004. PMID: 16036093 Review.
-
[Osteoporosis therapy in general practice. Which measure should be included?].MMW Fortschr Med. 2002 Oct 17;144(42):62. MMW Fortschr Med. 2002. PMID: 12534001 German. No abstract available.
-
Effective strategies to identify postmenopausal women at risk for osteoporosis.Geriatrics. 2007 Nov;62(11):22-30. Geriatrics. 2007. PMID: 17999567 Review.
-
Use of highly potent bisphosphonates in the treatment of osteoporosis.Curr Osteoporos Rep. 2003 Dec;1(3):116-22. doi: 10.1007/s11914-996-0006-5. Curr Osteoporos Rep. 2003. PMID: 16036074 Review.
Cited by
-
Decoding the mechanism of Eleutheroside E in treating osteoporosis via network pharmacological analysis and molecular docking of osteoclast-related genes and gut microbiota.Front Endocrinol (Lausanne). 2023 Nov 7;14:1257298. doi: 10.3389/fendo.2023.1257298. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027135 Free PMC article.
-
MiR-218-5p-dependent SOCS3 downregulation increases osteoblast differentiation inpostmenopausal osteoporosis.J Orthop Surg Res. 2023 Feb 15;18(1):109. doi: 10.1186/s13018-023-03580-4. J Orthop Surg Res. 2023. PMID: 36793115 Free PMC article.
-
Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis.Front Pharmacol. 2022 May 24;13:888208. doi: 10.3389/fphar.2022.888208. eCollection 2022. Front Pharmacol. 2022. PMID: 35685637 Free PMC article.
-
Analysis and Validation of Hub Genes in Blood Monocytes of Postmenopausal Osteoporosis Patients.Front Endocrinol (Lausanne). 2022 Jan 13;12:815245. doi: 10.3389/fendo.2021.815245. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35095774 Free PMC article.
-
Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.Calcif Tissue Int. 2021 Jul;109(1):44-54. doi: 10.1007/s00223-021-00819-2. Epub 2021 Feb 24. Calcif Tissue Int. 2021. PMID: 33625534